Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update
SON-1010, fully-human IL-12 configured using FHAB platform, advancing towards IND submission At-The-Market offering program resulted in net proceeds of $10.2...